Overview

Study of OT202 in Treating Moderate to Severe Dry Eye

Status:
COMPLETED
Trial end date:
2024-01-26
Target enrollment:
Participant gender:
Summary
This is a phase II study to explore the optimal dosage of OT202 in treating dry eye.
Phase:
PHASE2
Details
Lead Sponsor:
Ocumension Therapeutics (Shanghai) Co., Ltd